Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293439 | 0.91 | P2RX4 (0.32) | — | |
| SCHEMBL16293851 | 0.91 | LMNA (0.30) | LMNASMN1; SMN2 | |
| SCHEMBL16294225 | 0.90 | LMNA (0.36) | LMNASMN1; SMN2 | |
| SCHEMBL17700725 | 0.89 | LMNA (0.35) | LMNASMN1; SMN2 | |
| SCHEMBL17144781 | 0.86 | LMNA (0.33) | LMNASMN1; SMN2 | |
| SCHEMBL16293461 | 0.86 | CYP19A1 (0.35) | — | |
| SCHEMBL16294437 | 0.84 | LMNA (0.35) | LMNASMN1; SMN2 | |
| SCHEMBL16293529 | 0.83 | GAA (0.36) | SMN1; SMN2 | |
| SCHEMBL16294177 | 0.82 | L3MBTL1 (0.37) | LMNASMN1; SMN2 | |
| SCHEMBL16294916 | 0.82 | CACNA1H (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
| EP-3008052-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014201073-A9 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2014201073-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | LMNA 963/4885SMN1; SMN2 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.